Effect of early adjunctive use of oral sildenafil and inhaled nitric oxide on the outcome of pulmonary hypertension in newborn infants. A feasibility study

Journal of Neonatal-Perinatal Medicine

Volumn 9, Issue 3, 2016, Pages 251-259

  Al Omar, S ^a   Salama, H ^a   Al Hail, M ^a   Al Rifai, H ^a   Bunahia, M ^a   El Kasem, W ^a   Siddiqui, F J ^a   Dilawar, M ^a   Yassin, H ^a   Masud, F ^a   Mohamed, A ^a   Mansour, A ^a  

^a Women's Hospital   (Qatar)

Author keywords

hypertension; iNO; Newborn; oxygen index; pulmonary; respiratory; sildenafil

Indexed keywords

ALKALINE PHOSPHATASE; ARTIFICIAL LUNG SURFACTANT; ASPARTATE AMINOTRANSFERASE; CREATININE; NITRIC OXIDE; PLACEBO; SILDENAFIL; UREA; VASODILATOR AGENT;

ABDOMINAL DISTENSION; ADJUVANT THERAPY; ARTICLE; ARTIFICIAL VENTILATION; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOPPLER ECHOCARDIOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; EARLY INTERVENTION; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GAS ANALYSIS PARAMETERS; HEMATEMESIS; HUMAN; KIDNEY FUNCTION; LEUKOCYTE COUNT; LEUKOPENIA; LIVER FUNCTION; MALE; MECONIUM ASPIRATION; MELENA; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEUTROPHIL COUNT; NEWBORN; OXYGEN INDEX; PARTIAL THROMBOPLASTIN TIME; PERSISTENT PULMONARY HYPERTENSION; PNEUMONIA; PNEUMOTHORAX; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; REBOUND; SEIZURE; SEPSIS; SIDE EFFECT; STOMACH HEMORRHAGE; THROMBOCYTE COUNT; TREATMENT DURATION; UREA BLOOD LEVEL; VOMITING; EPIDEMIOLOGY; NEBULIZER; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PERSISTENT FETAL CIRCULATION SYNDROME; PREMATURITY; QATAR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; DOUBLE-BLIND METHOD; FEASIBILITY STUDIES; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; MALE; NEBULIZERS AND VAPORIZERS; NITRIC OXIDE; PERSISTENT FETAL CIRCULATION SYNDROME; PROSPECTIVE STUDIES; QATAR; SILDENAFIL CITRATE; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 84988345209     PISSN: 19345798     EISSN: 18784429     Source Type: Journal    
DOI: 10.3233/NPM-16161     Document Type: Article

References (38)

1. Boden G, Bennett C. The management of persistent pulmonary hypertension of the newborn. Paediatr Child Health 2004;14:290-7.
2. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115:343-9.
3. Channick RN, Newhart JW, Johnson FW, et al. Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: An ambulatory delivery system and initial clinical tests. Chest 1996;109:1545-9.
4. Travadi JN, Patole SK. Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: A review. Pediatr Pulmonol 2003;36:529-35.
5. Kelly LK, Porta NF, Goodman DM, Carroll CL, Steinhorn RH. Inhaled prostacyclin for term infants with persistent pulmonary hypertension refractory to inhaled nitric oxide. J Pediatr 2002;141:830-2.
6. Sola A, Baquero H. Sildenafil oral en medicina neonatal "Investigado para adultos, usado tambie"n por neonatos. An Pediatr (Barc) 2007;66:167-76.
7. Beavo JA. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol Rev 1995;75:725-48.
8. Buck ML. Sildenafil for the treatment of pulmonary hypertension in children. Pediatr Pharm 2004;10:1-4.
9. Weimann J, Ullrich R, Hromi J, et al. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology 2000;92:1702-12.
10. Shekerdemian LS, Ravn HB, Penny DJ. Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension. Am J Respir Crit Care Med 2002;165:1098-102.
11. Sastry BKS, Narasimhan C, Reddy NK, et al. A study of clinical efficacy of sildenafil in patients with primary pulmonary hypertension. Indian Heart J 2002;54:410-14.
12. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA recommends against use of Revatio [sildenafil] in children with pulmonary hypertension. 2012 Dec 13. http://www.fda.gov/Drugs/DrugSafety/ ucm317123.htm.
13. Singh TP, Rohit M, Grover A, Malhotra S, Vijayvergiya R. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J 2006;151:851;e1-5.
14. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: Comparison with inhaled nitric oxide. Circulation 2002;105:2398-403.
15. Prasad S,Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension. N Engl JMed 2000;343:1342-43.
16. Erickson S, Reyes J, Bohn D, et al. Sildenafil (Viagra) in childhood and neonatal pulmonary hypertension. J AmColl Cardiol 2002;39:402A (abstract).
17. Fernández Gonzáleza N, Rodríguez Fernándeza A, Jerez Rojas J, et al. Sildenafilo oral como tratamiento de un neonato con hipertensión pulmonar persistente. An Pediatr (Barc) 2004;61:567-8.
18. Bonino A, Moraes M, Mortinotti M, et al. Sildenafil una alternativa para el tratamiento de la hipertensión pulmonar persistente? Arch Pediatr Urug 2005;76:130-4.
19. Namachivayam P, Theilen U, ButtWW, Cooper SM, Penny DJ, Shekerdemian LS. Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am J Respir Crit Care Med 2006;174:1042-7.
20. Herrera Torres R, Concha Gonzalez EP, Holberto Castillo J, et al. Sildenafil oral como alternativa en el tratamiento de recién nacidos con hipertensión pulmonar persistente. Rev Mex Pediatr 2006;73:159-63.
21. Baquero H, Soliz A, Neira F, Venegas ME, Sola A. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn:Apilot randomized blinded study. Pediatrics 2006;117:1077-83.
22. Uslu S, Kumtepe S, Bulbul A, Comert S, Bolat F, Nuhoglu A. A comparison of magnesium sulphate and sildenafil in the treatment of the newborns with persistent pulmonary hypertension: A randomized controlled trial. J Trop Pediatr 2011;57(4):245-50.
23. Vargas-Origel A, Gómez-Rodriguez G, Aldana-Valenzuela C, et al. The use of sildenafil in persistent pulmonary hypertension of the newborn. Am J Perinatol 2010;27:225-30.
24. Peter M, Marci K, Sontag, Dunbar Ivy D, Steven Abman H. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr 2009;154(3):379-84, 384.e1-2.
25. Keller RL, Hamrick SE, Kitterman JA, Fineman JR, Hawgood S. Treatment of rebound and chronic pulmonary hypertension with oral sildenafil in an infant with congenital diaphragmatic hernia. Pediatr Crit Care Med 2004;5: 184-7.
26. Shah PS, Ohlsson A. Sildenafil for pulmonary hypertension in neonates. Cochrane Database Syst Rev 2011;8:CD005494.
27. Ellsworth MA, Harris MN, Carey WA, Spitzer AR, Clark RH. Off-Label Use of Inhaled Nitric Oxide after release of NIH consensus statement. Pediatrics 2015;135(4)643-8.
28. Cabral J, Belik J. Persistent pulmonary hypertension of the newborn: Recent advances in pathophysiology and treatment. J Pediatr (Rio J) 2013;89:226-42.
29. Su BH, Watanabe T, Shimizu M, et al. Doppler assessment of pulmonary artery pressure in neonates at risk of chroniclung disease. Arch Dis Child Fetal Neonatal Ed 1997; 77:F23-27.
30. Berger M, Haimowitz A,Van Tosh A, Berdoff RL, Goldberg E. Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol 1985;6:359-65.
31. Lemus-Varela ML, Sola A, Gómez-Meda BC. Oral sildenafil citrate lacks genotoxicity and cytotoxicity in a primate model: Callithrix jacchus. J Perinatol 2006;26:423-7.
32. Marsh CS, Marden B, NewsomR. Severe retinopathy of prematurity [ROP] in a premature baby treated with sildenafil acetate [Viagra] for pulmonary hypertension. Br J Ophthalmol 2004;88:306-7.
33. Abrams D, Schulze-Neick I, Magee AG. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 2000;84:e4.
34. Travardi JN, Patole SK. Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: A review. Pediatr Pulmonol 2003;36:529-35.
35. Oral sildenafil as an alternative treatment in the persistent pulmonary hypertension in newborns. RevMex Pediatr 2006;73:107-11.
36. Khorana M,Yookaseam T, Layangool T, Kanjanapattanakul W, Paradeevisut H. Outcome of oral sildenafil therapy on persistent pulmonary hypertension of the newborn at queen Sirikit National Institute of Child Health. JMed Assoc Thai 2011;94:S64-73.
37. Stocker C, Penny DJ, Brizard CP, Cochrane AD, Soto R, Shekerdemian LS. Intravenous sildenafil and inhaled nitric oxide: A randomized trial in infants after cardiac surgery. Intensive Care Med 2003;29:1996-2003.
38. Matamis D, Pampori S, Papathanasiou A, et al. Inhaled NO and sildenafil combination in cardiac surgery patients with out-of-proportion pulmonary hypertension: Acute effects on postoperative gas exchange and hemodynamics. Circ Heart Fail 2012;5(1):47-53.